ELBIT MEDICAL TECHNOLOGIES LTD Inactive Instrument
Elbit Medical Technologies Ltd Share Price TEL AVIV STOCK EXCHANGE
Equities
EMTC-M
IL0004740150
Advanced Medical Equipment & Technology
| Sales 2022 | 0.05 0.21 4.32 | Sales 2023 | 0.35 1.32 27.86 | Capitalization | 6.56M 24.96M 525M |
|---|---|---|---|---|---|
| Net income 2022 | -5M -19.04M -400M | Net income 2023 | -17M -64.72M -1.36B | EV / Sales 2022 | 221,423,588 x |
| Net cash position 2022 | 2.25M 8.58M 180M | Net cash position 2023 | 1.65M 6.28M 132M | EV / Sales 2023 | 14,098,382 x |
| P/E ratio 2022 |
-2.61
x | P/E ratio 2023 |
-0.36
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 8.41% |
More Fundamentals
* Assessed data
| Managers | Title | Age | Since |
|---|---|---|---|
Ron Hadassi
CEO | Chief Executive Officer | 59 | 26/03/14 |
| Director of Finance/CFO | 51 | 31/12/17 | |
Daniel Spira
AUD | Comptroller/Controller/Auditor | 69 | 20/08/11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ron Hadassi
CEO | Chief Executive Officer | 59 | 26/03/14 |
Zvi Tropp
BRD | Director/Board Member | 84 | 13/05/20 |
Alon Bachar
BRD | Director/Board Member | 54 | 26/03/14 |
Elbit Medical Technologies Ltd is an Israel-based company engaged in the healthcare sector. It is a holding Company which was established in order to gather all of Elbit groups' bio medical and medical devices investments under one entity. Elbit Medical Technologies Ltd's medical division includes investment in InSightec Ltd that is engaged in the development, production and marketing of magnetic resonance imaging guided ultrasound equipment as well as investment in Gamida Cell Ltd that is engaged in the development of stem cell therapeutics based on its proprietary technologies for stem cell expansion as well as future regenerative cell-based medicines including heart tissue repair.
| 1st Jan change | Capi. | |
|---|---|---|
| -5.77% | 14.68B | |
| -40.71% | 2.71B | |
| -12.92% | 2.44B | |
| -8.78% | 1.51B | |
| -.--% | 1.12B | |
| +40.66% | 518M | |
| +91.79% | 502M | |
| +11.68% | 239M | |
| +1.67% | 183M |
